pentobarbital will reduce the extent or influence of bosentan by influencing hepatic enzyme CYP2C9/10 metabolism. Minimal/Importance Not known.
pentobarbital will lessen the extent or impact of amiodarone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will decrease the extent or effect of estropipate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital decreases effects of hemin by pharmacodynamic antagonism. Use Caution/Observe. Prescription drugs that raise delta-aminolevulinic acid synthetase may reduce hemin influence.
Reserve concomitant prescribing of such medication in clients for whom other therapy alternatives are insufficient. Restrict dosages and durations to your minimum amount expected. Watch closely for signs of respiratory depression and sedation.
Medication that have constraints other than prior authorization, quantity boundaries, and move therapy related to Every single prescription.
pentobarbital will decrease the level or outcome of abemaciclib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Coadministration of abemaciclib with robust CYP3A4 inducers cuts down plasma concentration of abemaciclib and its metabolites.
pentobarbital will reduce the extent or result of levoketoconazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.
With therapeutic doses of Nembutal Pentobarbital TCAs, barbiturates increase metabolism and reduce blood concentrations of TCAs.
pentobarbital will reduce the extent or effect of trazodone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will minimize the extent or result of methadone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
Observe Closely (1)pentobarbital will decrease the level or influence of exemestane by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. For patients acquiring exemestane by using a potent CYP3A4 inducer the encouraged dose of exemestane is 50 mg day by day following a food.
pentobarbital will lessen the level or impact of bedaquiline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Prevent coadministration of bedaquiline with solid CYP3A4 inducers as a consequence of prospective for lessened therapeutic result
pentobarbital will decrease the extent or outcome of imatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unfamiliar.